Comparing and evaluating the effect of 0.05% Zoledronate as medicated gel in gums for the treatment of patients with pyorrhoea alone and patients with pyorrhoea and diabetes.
- Conditions
- Health Condition 1: K053- Chronic periodontitis
- Registration Number
- CTRI/2020/05/025188
- Lead Sponsor
- SCB Dental College and Hospital Cuttack
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Systemically healthy patient (except for well controlled Type 2 DM).
2. Pocket depths >= 5mm measured with UNC 15 probe.
3. Clinical attachment loss >= 4mm measured with UNC 15 probe.
4. Vertical bone loss >= 3mm seen on intraoral periapical radiograph.
5. Patients with well controlled Type 2 Diabetes Mellitus classified based on
criteria of American Diabetic Association (ADA) and glycated haemoglobin
levels (HbA1C).
6. No history of periodontal therapy in the preceding 6 months.
7. No use of antibiotics in the preceding 6 months.
8. Non smokers
1. With known systemic disease (other than type 2 diabetes)
2. With known or suspected allergy to ZLN/ bisphosphonate group.
3. Those on systemic ZLN/Bisphosphonate therapy
4. Individuals with Aggressive periodontitis
5. Use of tobacco in any form and alcohol
6. Immunocompromised individuals
7. Pregnant or lactating females
8. Tooth with hopeless prognosis.
9. Serum creatinine clearance Ë? 35ml/min or in patients with
evidence of acute renal impairment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in radiographic defect depth reduction percentage from baseline.Timepoint: 3 months and 6 months.
- Secondary Outcome Measures
Name Time Method Change in Probing depths, Clinical attachment <br/ ><br>levels, Modified sulcular bleeding index, and Plaque index from baseline.Timepoint: 3 months and 6 months